Abstract: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.

Abstract: A method for identifying anomalies in time series data, the method comprising the steps of computing parity vectors for one or more data points in a predetermined sample of data points in the time series, the parity vector representing redundancy between an estimated true value and an error term for each of the said one or more data points, evaluating the parity vectors to determine a set of the parity vectors in a selected direction; and evaluating a statistical distribution of the set according to a predetermined criterion to determine a data point to be corrected whose parity vectors satisfy the criterion in the distribution.

Abstract: Disclosed are novel compounds according to general formula (I), which have shown OT agonist activity.

Abstract: The present invention relates to human PGF polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques, and antibodies and antagonist/inhibitors against such polypeptides. Also provided are methods of using such polypeptides therapeutically for treating prostate cancer, to promote tissue regeneration and to facilitate wound healing. Also provided is a diagnostic assay to detect prostate cancer and benign prostatic hyperplasia.

Abstract: The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.

Abstract: Provided is a method for the mutation, synthesis and selection of a protein of interest, by first incubating a replicable RNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, such that the RNA-directed RNA polymerase replicates the RNA molecule but introduces mutations thereby generating a population of mutant RNA molecules. The mutant RNA molecules are then incubated with a translation system under conditions which result in the synthesis of a population of mutant proteins. After translation, the mutant proteins are linked to their encoding RNA molecules, and one or more mutant proteins of interest are selected.

Abstract: Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9–11) are new. Compounds according to the invention are vasopressin V2 receptor agonists.

Abstract: Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.

Abstract: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ?O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ?O or ?S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

Abstract: An article of footwear includes a sole having a different performing lateral and medial regions. Ground engaging members, such as cleats, provide traction and one of the regions, preferably the lateral region, includes a stability member extending from the sole and spanning between a pair of adjacent ground engaging members in a heel to toe direction. The ground engaging members may have a body and a tip portion. Each tip portion may be integrally formed with all or a portion of its respective body. The medial and lateral regions include buttressing member having different characteristics and dimensions for strengthening the ground engaging members with providing enhanced flexibility.

Abstract: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the other is H, or V1 and V2 together are ?O, —O(CH2)pO— or —S(CH2)pS—; W1 is either O or S; X1 and X2 are both H, or together are ?O or ?S; Y is OR5 or NR6R7; R1, R2, R3 and R4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R5 is selected from H and lower alkyl; R6 and R7 are independently selected from H and lower alkyl, or together are —(CH2)n—; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.

Abstract: The present invention relates to the field of evolution of nucleic acids in vivo and provides methods and compositions for introducing diversity into gene products. The present invention allows generation of new sequences that have desirable properties by virtue of high frequency mutation events within a cell. The high frequency mutation of a polynucleotide sequence results in, the production of a large population of new sequence variants. Appropriate selection and/or screening permits identification and isolation of mutant forms of the polynucleotide sequence as well as products resulting from expression of the mutant sequences.

Abstract: A soccer shoe includes an upper and a cleat assembly coupled to the upper. The cleat assembly further includes a medial support bar located on the medial side and a lateral support bar located on the lateral side. A portion of the cleat assembly located near a midfoot section of the medial support bar is stiffer than a portion of the cleat assembly located near a midfoot section of the lateral support bar. The medial support bar extends approximately from a region corresponding to the rear of the calcaneous of a properly fitted wearer to approximately the head of the first metatarsal of the wearer. The lateral support bar extends approximately from a region corresponding to the rear of the calcaneous of the wearer to approximately the head of the fifth metatarsal of the wearer. The cleat assembly is bonded to a cushioning midsole formed from heated and compressed ethylene vinyl acetate foam. The upper lacks a full-length lasting board and is bonded directly to the cushioning midsole.

Abstract: A rotatable selector mechanism for a motor vehicle transmission has a selector knob rotatable in a housing to select an operating mode of the transmission among a number of selector positions indicated by a label (P,R,N,D,M). The selector mechanism further includes a detent plate which cooperates with a detent pin for maintaining the selector knob in each of positions. The detent plate is connected to position sensors for generating selector signals to a transmission control unit which supplies control signals to an actuator for operate the transmission according to the operating mode selected. The detent plate is also associated to the selector knob and to a drive correction means by means of clutch devices respectively to engage the detent plate to one of the selector knob and the drive correction means.

Abstract: A cleated article of footwear includes a chassis assembly having a sole plate having a plurality of bosses extending from a lower surface thereof. A heel counter extends upwardly from a heel portion of the sole plate. An outer assembly is secured to the chassis assembly and includes a sole portion and an upper secured to the sole portion. A plurality of cleats extends downwardly from a lower surface of the sole portion. Each of a plurality of apertures extends downwardly into a corresponding cleat and receives a boss.

Abstract: An article of footwear includes a sole assembly, an upper secured to the sole assembly, a heel counter secured to the upper, and a heel pad removably attached to an inner surface of the heel counter.

Abstract: Compounds according to general formula (1), wherein G1 is NR5R6 or a fused polycyclic group are novel. They are selective and potent oxytocin agonists. Pharmaceutical compositions of such compounds are useful in the treatment of, inter alia, erectile dysfunction.

Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death.

Abstract: A soccer shoe includes an upper and a cleat assembly coupled to the upper. The cleat assembly further includes a medial support bar located on the medial side and a lateral support bar located on the lateral side. A portion of the cleat assembly located near a midfoot section of the medial support bar is stiffer than a portion of the cleat assembly located near a midfoot section of the lateral support bar. The medial support bar extends approximately from a region corresponding to the rear of the calcaneous of a properly fitted wearer to approximately the head of the first metatarsal of the wearer. The lateral support bar extends approximately from a region corresponding to the rear of the calcaneous of the wearer to approximately the head of the fifth metatarsal of the wearer. The cleat assembly is bonded to a cushioning midsole formed from heated and compressed ethylene vinyl acetate foam. The upper lacks a full-length lasting board and is bonded directly to the cushioning midsole.

Abstract: Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9-11) are new. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.